Breaking News Instant updates and real-time market news.

MOR

MorphoSys

$27.63

-0.105 (-0.38%)

, JNJ

Johnson & Johnson

$145.38

-0.52 (-0.36%)

05:06
12/10/18
12/10
05:06
12/10/18
05:06

MorphoSys upgraded to Buy from Hold at Deutsche Bank

Deutsche Bank analyst Gunnar Romer upgraded MorphoSys (MOR) to Buy and raised his price target for the shares to EUR 130 from EUR 120. The company's 115 antibody drug candidates offer "best-in-class risk diversification and value-creation potential," Romer tells investors in a research note. Further, he believes Tremfya, which is partnered with Johnson & Johnson (J&J), is on its way to becoming a multi-billion blockbuster.

MOR

MorphoSys

$27.63

-0.105 (-0.38%)

JNJ

Johnson & Johnson

$145.38

-0.52 (-0.36%)

  • 12

    Dec

  • 12

    Dec

MOR MorphoSys
$27.63

-0.105 (-0.38%)

11/05/18
PIPR
11/05/18
INITIATION
Target $38
PIPR
Overweight
MorphoSys initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Danielle Brill started MorphoSys with an Overweight rating and $38 price target. Despite last week's rally, the analyst thinks the company's lead asset MOR208 remains underappreciated. The data look "significantly better than other high-profile drugs in development," Brill tells investors in a research note. She expects good adoption of the drug and thinks MorphoSys shares are undervalued
11/28/18
PIPR
11/28/18
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys's MOR208 remains key focus for company, says Piper Jaffray
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $38 price target on MorphoSys following her meeting with its CEO Simon Maroney at Piper Jaffray Healthcare Conference. The analyst notes that the company remains focused on the development of MOR208 and believes that the drug could become "cornerstone" of Diffuse Large B-Cell Lymphoma, or DBLCL, therapy, remaining "very bullish" on the name. Brill adds that her survey of doctors treating lymphoma at the conference revealed that 46% would use MOR208 for their DBLCL patients.
12/02/18
PIPR
12/02/18
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys' MOR208 ASH data 'remarkable,' says Piper Jaffray
Piper Jaffray analyst Danielle Brill notes that MorphoSys presented MOR208 data at ASH, and says she is particularly encouraged that MOR208 efficacy is consistent across of cell-of-origin and in rituximab refractory patients. "It's difficult to poke holes in the data which were deemed remarkable by the lead investigator," she contends. Brill thinks MOR208 has made it onto the radar screens of physicians and has huge potential in DLBCL. Additionally, the analyst thinks the next likely catalyst is an "attractive partnership" for MOR208 development and commercialization outside of the U.S. She reiterated an Overweight rating and $38 price target on the shares.
12/06/18
PIPR
12/06/18
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys share setup remains positive, says Piper Jaffray
Updates at MorphoSys AG's investor day were incremental, though future development plans for MOR208 in front-line diffuse large B-cell lymphoma were outlined, Piper Jaffray analyst Danielle Brill tells investors in a research note. While the analyst hoped pivotal development in the front-line setting would begin sooner than mid-2020, she appreciates "de-risking" the program by running a small study first. She continues to think the setup for MorphoSys is positive and keeps an Overweight rating on the shares with a $38 price target.
JNJ Johnson & Johnson
$145.38

-0.52 (-0.36%)

11/12/18
PIPR
11/12/18
NO CHANGE
Target $25
PIPR
Overweight
Arrowhead's new data validate TRiM pipeline, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes new data presented by Arrowhead (ARWR) at the AASLD meeting on ARO-AAT and ARO-HBV validate the company's proprietary TRiM platform. He expects a potentially registrational Phase 2/3 trial for ARO-AAT to start in the first quarter of 2019 and noted that partner Janssen (JNJ) intends to begin Phase 2 studies of ARO-HBV in the first half of next year. Tenthoff keeps an Overweight rating and $25 price target on Arrowhead shares.
11/13/18
LEER
11/13/18
INITIATION
Target $18
LEER
Outperform
AC Immune initiated with an Outperform at Leerink
Leerink analyst Marc Goodman started AC Immune with an Outperform and $18 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding AC Immune, Goodman notes that it has a diversified pipeline of drug candidates and diagnostics for Alzheimer's disease led by a late stage antibody with crenezumab, and has strong partners with Roche (RHHBY) for crenezumab, Johnson & Johnson (JNJ) for Anti-Tau vaccine, Biogen (BIIB) for alphasynuclein-PET tracer diagnostic, and Piramal for TauPET tracer diagnostic.
11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
12/03/18
PIPR
12/03/18
NO CHANGE
PIPR
Argenx price target raised to $161 from $154 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating on Argenx and raised his price target on shares to $161 from $154. Tenthoff noted that after the company announced a 92% response rate for 11/12 AML patients in the Phase I cusatuzumab plus azacitidine study, it signed a global licensing deal with Johnson & Johnson (JNJ)/Janssen's European subsidiary Cilag for $300M in cash and a $200M equity investment, bringing pro forma cash to $1.16B. The analyst also noted that Argenx was eligible for $1.3B in milestones and that it retained 50/50 U.S. profit share and double-digit OUS royalties. Tenthoff concluded that "the updated analysis removes any concern investors had over bleeding events."

TODAY'S FREE FLY STORIES

NFLX

Netflix

$310.48

-1.4 (-0.45%)

, DIS

Disney

$148.25

1.34 (0.91%)

18:09
11/22/19
11/22
18:09
11/22/19
18:09
Periodicals
Netflix internal data shows company not hurt by Disney+, Bloomberg says »

Netflix's (NFLX)…

NFLX

Netflix

$310.48

-1.4 (-0.45%)

DIS

Disney

$148.25

1.34 (0.91%)

AAPL

Apple

$261.81

-0.23 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

TMUS

T-Mobile

$78.59

0.89 (1.15%)

18:08
11/22/19
11/22
18:08
11/22/19
18:08
Periodicals
T-Mobile says some customers affected by data breach, Bloomberg reports »

T-Mobile said that hacker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 09

    Dec

WVE

Wave Life Sciences

$30.43

0.2 (0.66%)

18:05
11/22/19
11/22
18:05
11/22/19
18:05
Hot Stocks
Wave Life Sciences director Verdine sells 30K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$371.18

4.71 (1.29%)

17:42
11/22/19
11/22
17:42
11/22/19
17:42
Periodicals
Canada agency: Official's email on 737 reflects working-level view, Reuters says »

Canadian regulator…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CACI

CACI

$231.32

-4.2 (-1.78%)

17:36
11/22/19
11/22
17:36
11/22/19
17:36
Hot Stocks
CACI awarded $112.53M Army contract modification »

CACI was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

AGO

Assured Guaranty

$48.65

-0.03 (-0.06%)

17:35
11/22/19
11/22
17:35
11/22/19
17:35
Hot Stocks
Assured Guaranty CIO buys 25.5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$310.48

-1.4 (-0.45%)

, DIS

Disney

$148.25

1.34 (0.91%)

17:33
11/22/19
11/22
17:33
11/22/19
17:33
Periodicals
Netflix internal data shows company not hurt by Disney+, Bloomberg says »

Netflix's (NFLX)…

NFLX

Netflix

$310.48

-1.4 (-0.45%)

DIS

Disney

$148.25

1.34 (0.91%)

AAPL

Apple

$261.81

-0.23 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

OYST

Oyster Point Pharma

$14.84

0.64 (4.51%)

17:24
11/22/19
11/22
17:24
11/22/19
17:24
Hot Stocks
Oyster Point Pharma discloses 'positive' Phase 1 results for OC-01 nasal spray »

Oyster Point Pharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SACH

Sachem Capital

$4.21

(0.00%)

17:19
11/22/19
11/22
17:19
11/22/19
17:19
Hot Stocks
Sachem Capital co-CEO Villano steps down »

Sachem Capital announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$57.63

-0.61 (-1.05%)

17:18
11/22/19
11/22
17:18
11/22/19
17:18
Hot Stocks
Intel board member Goetz buys $5.04M in stock »

Intel board member James…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 09

    Dec

  • 23

    Jan

SWAV

ShockWave Medical

$38.00

0.18 (0.48%)

17:12
11/22/19
11/22
17:12
11/22/19
17:12
Hot Stocks
ShockWave Medical CEO sells 30K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAEX

SAExploration

$2.61

0.16 (6.53%)

17:01
11/22/19
11/22
17:01
11/22/19
17:01
Hot Stocks
SAExploration receives Nasdaq non-compliance letter »

SAExploration Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OFG

OFG Bancorp

$20.48

0.17 (0.84%)

17:00
11/22/19
11/22
17:00
11/22/19
17:00
Hot Stocks
OFG Bancorp buys 40K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MO

Altria Group

$49.00

0.17 (0.35%)

, BTI

British American Tobacco

$38.15

-0.21 (-0.55%)

16:47
11/22/19
11/22
16:47
11/22/19
16:47
Periodicals
POTUS in favor of raising minimum vaping age to 21, MarketWatch says »

U.S. President Donald…

MO

Altria Group

$49.00

0.17 (0.35%)

BTI

British American Tobacco

$38.15

-0.21 (-0.55%)

IMBBY

Imperial Brands

$0.00

(0.00%)

PM

Philip Morris

$82.39

-1.08 (-1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

HIBB

Hibbett Sports

$28.64

3.57 (14.24%)

16:45
11/22/19
11/22
16:45
11/22/19
16:45
Recommendations
Hibbett Sports analyst commentary  »

Hibbett Sports price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

MSCI

MSCI

$257.97

2.295 (0.90%)

16:43
11/22/19
11/22
16:43
11/22/19
16:43
Hot Stocks
MSCI COO sells 6,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$39.53

0.54 (1.39%)

, VIA

Viacom

$26.06

-0.03 (-0.11%)

16:35
11/22/19
11/22
16:35
11/22/19
16:35
Hot Stocks
CBS to list ViacomCBS shares on Nasdaq following merger »

CBS Corporation (CBS)…

CBS

CBS

$39.53

0.54 (1.39%)

VIA

Viacom

$26.06

-0.03 (-0.11%)

VIAB

Viacom

$23.64

0.38 (1.63%)

ICE

IntercontinentalExchange

$93.70

-0.19 (-0.20%)

NDAQ

Nasdaq

$104.36

-0.31 (-0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DIS

Disney

$148.25

1.34 (0.91%)

16:32
11/22/19
11/22
16:32
11/22/19
16:32
Periodicals
Disney sees 'Frozen 2' having possible $40M opening day, Bloomberg says »

Disney told Bloomberg it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCRH

Blue Capital

$7.00

(0.00%)

16:31
11/22/19
11/22
16:31
11/22/19
16:31
Hot Stocks
Blue Capital declares special distribution of 57c per common share »

Blue Capital Reinsurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
11/22/19
11/22
16:30
11/22/19
16:30
Options
Preliminary option volume of 18.4M today »

Preliminary option volume…

STX

Seagate

$59.27

-0.21 (-0.35%)

16:24
11/22/19
11/22
16:24
11/22/19
16:24
Hot Stocks
Seagate chairman sells 90K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEL

American Equity

$29.12

0.155 (0.54%)

16:21
11/22/19
11/22
16:21
11/22/19
16:21
Hot Stocks
American Equity raises annual dividend 7% to 30c per share »

American Equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
11/22/19
11/22
16:20
11/22/19
16:20
Options
Closing CBOE SPX and VIX Index summary for November 22nd »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$49.25

0.4 (0.82%)

16:18
11/22/19
11/22
16:18
11/22/19
16:18
Hot Stocks
Morgan Stanley's Rooney sells over 50,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 06

    Dec

TSLA

Tesla

$332.91

-21.91 (-6.18%)

, GPS

Gap

$16.92

0.7 (4.32%)

16:17
11/22/19
11/22
16:17
11/22/19
16:17
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks ended the session…

TSLA

Tesla

$332.91

-21.91 (-6.18%)

GPS

Gap

$16.92

0.7 (4.32%)

UBER

Uber

$29.57

0.11 (0.37%)

CVX

Chevron

$118.62

-0.18 (-0.15%)

LB

L Brands

$18.01

0.83 (4.83%)

JWN

Nordstrom

$37.96

3.67 (10.70%)

SPLK

Splunk

$140.52

13.72 (10.82%)

PSTG

Pure Storage

$16.85

-2.99 (-15.07%)

FL

Foot Locker

$40.24

-1.22 (-2.94%)

WSM

Williams-Sonoma

$67.44

-1.325 (-1.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 02

    Dec

  • 04

    Dec

  • 05

    Dec

  • 09

    Dec

  • 12

    Dec

  • 27

    Feb

  • 10

    Mar

  • 11

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.